Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

Abstract Number: 0246 • ACR Convergence 2024
Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies
Elana Shaw, Stephanie Glavaris, Brian Mog, Alexander Pearlman, Sarah DiNapoli, Jin Liu, Kyle J. Kaeo, Kenneth W. Kinzler, Chetan Bettegowda, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially deadly immune complication after infection with SARS-CoV-2. In patients with MIS-C, a striking…
Abstract Number: 1131 • ACR Convergence 2024
Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis
Vivian Laquer¹, Leon Kircik², Neil Sadick³, Jamie Weisman⁴, Yiwei Zhao⁵, Jessamyn Blau⁵, Wenwen Zhang⁶, Jonathan Uy⁵, Warren Winkelman⁶ and Melinda Gooderham⁷, ¹First OC Dermatology Research, Fountain Valley, CA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴Piedmont Atlanta, Atlanta, GA, ⁵Takeda Development Center Americas, Inc., Cambridge, MA, ⁶Takeda Development Center Americas, Inc., Cambridge, ⁷SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada
Background/Purpose: Zasocitinib (TAK-279) is a highly selective, allosteric, oral inhibitor of tyrosine kinase 2 (TYK2). TYK2 mediates signaling from cytokines involved in the pathogenesis of…
Abstract Number: 0287 • ACR Convergence 2024
Joint Involvement in Cystic Fibrosis: Description of Clinical Phenotypes
Omar Al Tabaa¹, manon Lesturgie¹, Pierre Régis Burgel², Nicolas Carlier² and Jérôme Avouac³, ¹Rheumatology Department, Cochin Hospital, Paris, France, ²Pulmonology department, Cochin Hospital, Paris, France, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Cystic fibrosis (CF) is the most common lethal autosomal recessive genetic disorder. The improvement in life expectancy due to the advent of new treatments…
Abstract Number: 1224 • ACR Convergence 2024
Occupational Stress and Fibromyalgia Among Healthcare Professionals in Abu Dhabi Region, United Arab Emirates: A Cross-sectional Study
Shamma Al Nokhatha¹, Asma Alneyadi², Noor Alnuaimi³, Hajar Almansoori³, Sara Alhosani³, Shammah Almemari⁴ and Muhammad Hashim³, ¹Tawam hospital/ College of Medicine and Health Sciences, Al Ain, Abu Dhabi, United Arab Emirates, ²Tawam hospital, Al Ain, Abu Dhabi, United Arab Emirates, ³College of Medicine and Health Sciences, Al Ain, Abu Dhabi, United Arab Emirates, ⁴Ambulatory Health Services, Al Ain, Abu Dhabi, United Arab Emirates
Background/Purpose: The stress level of healthcare workers may impact the quality of care provided to patients. The prevalence of occupational stress among healthcare workers can…
Abstract Number: 0295 • ACR Convergence 2024
Mycophenolate Mofetil in the Treatment of Patients with Isolated Cardiac Sarcoidosis
Namitha Nair¹, Leen Al Saleh², Haya Haddad³, Maria Jaimes Reyes⁴, Vishakha Chetram⁵, Farooq Sheikh⁶, FLORINA CONSTANTINESCU⁷ and Anjani Pillarisetty⁸, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Watson Clinic, Lakeland, FL, ³Medstar Washington Hospital Center, Silver Spring, MD, ⁴Medstar Washington Hospital Center/Georgetown University, Washington, DC, ⁵Inova Schar Heart and Vascular, Falls Chirch, VA, ⁶MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Washington, DC, ⁷MedStar Washington Hospital Center, Washington, DC, ⁸Carson Tahoe Medical Group, Reno, NV
Background/Purpose: Cardiac involvement is seen in approximately a fourth of patients with sarcoidosis, a non-necrotizing granulomatous systemic disease. Among these patients, 25% may have isolated cardiac…
Abstract Number: 1299 • ACR Convergence 2024
Board-Style Rheumatology Teaching for Medicine Residents: Novel Approach to Curriculum Development
Merve Aksoy*, Shadi Jafari-Esfahani*, Yasaman Ahmadzadeh and Katarzyna Gilek-Seibert, Roger Williams Medical Center, Providence, RI
Background/Purpose: During their training, internal medicine (IM) residents often have limited exposure to rheumatology, resulting in decreased confidence levels and inadequate scores on the In-training…
Abstract Number: 0299 • ACR Convergence 2024
Real-World Tolerability of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease
Saloni Goyal, Briana DiSilvio and Joanna Marco, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Nintedanib is an antifibrotic medication used to treat interstitial lung disease (ILD), including connective tissue disease-associated ILD (CTD-ILD). Clinical trials that led to its…
Abstract Number: 1688 • ACR Convergence 2024
Discovery and Validation of a New Classification of ANA-RMDs That Better Predict Long Term Outcomes Compared to Legacy Diagnoses
Jack Arnold¹, Lucy Carter¹, Yuzaiful Yusof², Zoe Wigston², Daniel Toro Dominguez³, Samuel Relton⁴, Guillermo Barturen⁵, Marta Alarcon-Riquelme⁶ and Edward Vital⁷, and PRECISESADS consortium, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, ³Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Andalucia, Spain, ⁴Leeds Institute of Data Analytics, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, ⁵Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁶Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom
Background/Purpose: ANA-associated RMDs (ANA-RMDs) include SLE, Sjogren’s, Scleroderma, Myositis, and mixed/undifferentiated CTD. Despite overlapping clinical and immunophenotypic features, there is significant disparity in access to…
Abstract Number: 0309 • ACR Convergence 2024
Characteristics and Factors Associated with Treatment Response Among Patients with Eosinophilic Fasciitis: A Systematic Review and Meta-analysis
Omar Hamdan¹, Roa'a Alshajrawi¹, Qais Mussa¹, Yazeed Alajlouni¹, Yazan Dabbah¹, Rawan Fratekh¹, Yousef Al-Mabrouk², Shatha Al-Mabrok² and Ahmad A. Toubasi¹, ¹University of Jordan, Amman, Jordan, ²Mansoura University, Al Mansoura, Egypt
Background/Purpose: To date, data on the clinical features, diagnosis and the treatment of Eosinophilic Fasciitis (EF) patients are mostly derived from individual case reports, with…
Abstract Number: 1715 • ACR Convergence 2024
Mortality Trends for Systemic Connective Tissue Diseases Across the United States from 1999 to 2020: A CDC-Wonder Database Analysis
Naima Khan¹, Yumna Furqan², Madiha Salman¹, Eman Ali¹, Wajeeh ur Rehman³, Ibtesam Allahi⁴, Farah Yasmin⁵ and Muhammad Sohaib Asghar⁶, ¹Dow University of Health Sciences, Karachi, Pakistan, ²Texas A&M School of Medicine, Dallas, TX, ³University Health Services Hospital, Johnson, NY, ⁴Allama Iqbal Medical College, Lahore, Pakistan, ⁵Yale University School of Medicine, New Haven, CT 06511, U.S.A., New Haven, CT, ⁶AdventHealth, Sebring, FL
Background/Purpose: The mortality burden of systemic connective tissue diseases (CTDs) is expected to rise in the U.S population because of multimorbidity and ageing. The primary…
Abstract Number: 0314 • ACR Convergence 2024
Microvascular Differences Between Acute and Chronic Cutaneous Graft versus Host Disease
Sehreen Mumtaz¹, Florentina Berianu², Benjamin Wang³, Breanna Cane⁴ and Olayemi Sokumbi⁴, ¹Mayo Clinic, Florida, Jacksonville, FL, ²mayo clinic, Ponte Vedra Beach, FL, ³Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: Cutaneous involvement in systemic sclerosis (SSc) and chronic sclerodermoid graft versus host disease (GVHD) is visibly indistinguishable and while characteristic nailfold videocapillaroscopy (NVC) patterns…
Abstract Number: 1843 • ACR Convergence 2024
Immune Responses to Herpes Zoster Vaccine Responses in Rheumatic Patients on JAK Inhibitors: Insights in Humoral and Cellular Response
cristiana sieiro santos¹, Juan Garcia Herrero², Jose Ordas Martínez³, Alejandra López Robles⁴, Carolina Álvarez Castro⁴, Ronald Colindres⁴, Estefanía Robles Martin⁴, Ana María Sahagún⁵ and Jose María Ruiz de Morales⁴, ¹Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ²Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵University of Leon, León, Spain
Background/Purpose: Patients with immune-mediated rheumatic diseases treated with JAK inhibitors face an elevated risk of herpes zoster (HZ) infection. Shingrix, a recombinant inactive vaccine, offers…
Abstract Number: 0318 • ACR Convergence 2024
The Relevance of a Positive ANA in New Patient Referrals to Rheumatology
Chi Chi Lau¹ and Ayesha Arif², ¹University of Vermont Medical Center, colchester, VT, ²University of Vermont Medical Center, Essex Junction, VT
Background/Purpose: A positive (+)ANA titer is a common reason for Rheumatology consultation, yet the ANA is a nonspecific, non-diagnostic, lab test that is positive in…
Abstract Number: 1984 • ACR Convergence 2024
Use of ICD Codes for the Identification of Patients with Immune Checkpoint Inhibitor Induced Inflammatory Arthritis
Tawnie Braaten¹, Madeline O’Sullivan¹, shardool Patel¹, Sauer brian², Jorge Rojas³, grant Cannon⁴ and miao Lai⁴, ¹UNIVERSITY OF UTAH, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Seattle VA, Mexico, Mexico, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: The identification of immune checkpoint inhibitor (ICI)-induced inflammatory arthritis (ICI-IA) using administrative data would provide a valuable advance in the investigation of ICI-IA. The…
Abstract Number: 0337 • ACR Convergence 2024
Characterization of Statin Induced Myopathy in the Hospital Setting
Olivia Yang¹, KUMAR VENKAT², Jeffery Durbin³ and Scott Kubomoto¹, ¹Riverside Community Hospital, Riverside, CA, ²Voluntary Clinical Associate Professor of Medicine -UCRSOM, Riverside, California, IRVINE, CA, ³HCA Healthcare Physicians Services Group, Brentwood, TN
Background/Purpose: Adverse effects of statin use involve the muscle and related rhabdomyolysis. Known risk factors for rhabdomyolysis include female sex, older age, Asian race, hypothyroidism,…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.